Zhang, H.Targher, G.Byrne, C.D.Kim, S.U.Wong, V.W.Valenti, L.Glickman, M.Ponce, J.Mantzoros, C.S.Crespo, J.Gronbaek, H.Yang, W.Eslam, M.Wong, R.J.Machado, M.V.Yu, M.Ghanem, O.M.Okanoue, T.Liu, J.Lee, Y.Xu, X.Pan, Q.Sui, M.Lonardo, A.Yilmaz, Y.Zhu, L.Moreno, C.Miele, L.Lupsor-Platon, M.Zhao, L.LaMasters, T.L.Gish, R.G.Zhang, H.Nedelcu, M.Chan, W.K.Xia, M.Bril, F.Shi, J.Datz, C.Romeo, S.Sun, J.Liu, D.Sookoian, S.Mao, Y.Méndez-Sánchez, N.Wang, X.Pyrsopoulos, N.T.Fan, J.Fouad, Y.Sun, D.Giannini, C.Chai, J.Xia, Z.Jun, D.W.Li, G.Treeprasertsuk, S.Li, Y.Cheung, T.T.Zhang, F.Goh, G.B.Furuhashi, M.Seto, W.Huang, H.Sessa, A.D.Li, Q.Cholongitas, E.Zhang, L.Silveira, T.R.Sebastiani, G.Adams, L.A.Chen, W.Qi, X.Rankovic, I.Ledinghen, V.D.Lv, W.Hamaguchi, M.Kassir, R.Müller-Wieland, D.Romero-Gomez, M.Xu, Y.Xu, Y.Chen, S.Kermansaravi, M.Kuchay, M.S.Lefere, S.Parmar, C.Lip, G.Y.H.Liu, C.Åberg, F.Lau, G.George, J.Sarin, S.K.Zhou, J.Zheng, M.Niriella, M.A. (MAFLD ICD-11 coding collaborators)2024-07-312024-07-312024Hepatology International. 2024(Online ahead of print)1936-0533 (Print)1936-0541 (Electronic)http://repository.kln.ac.lk/handle/123456789/27941Indexed in MEDLINE.BACKGROUND With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020, it is important to establish consensus for the coding of MAFLD in ICD-11. This will inform subsequent revisions of ICD-11.METHODS Using the Qualtrics XM and WJX platforms, questionnaires were sent online to MAFLD-ICD-11 coding collaborators, authors of papers, and relevant association members.RESULTS A total of 890 international experts in various fields from 61 countries responded to the survey. We also achieved full coverage of provincial-level administrative regions in China. 77.1% of respondents agreed that MAFLD should be represented in ICD-11 by updating NAFLD, with no significant regional differences (77.3% in Asia and 76.6% in non-Asia, p = 0.819). Over 80% of respondents agreed or somewhat agreed with the need to assign specific codes for progressive stages of MAFLD (i.e. steatohepatitis) (92.2%), MAFLD combined with comorbidities (84.1%), or MAFLD subtypes (i.e., lean, overweight/obese, and diabetic) (86.1%).CONCLUSIONS This global survey by a collaborative panel of clinical, coding, health management and policy experts, indicates agreement that MAFLD should be coded in ICD-11. The data serves as a foundation for corresponding adjustments in the ICD-11 revision.enGlobal surveyICD-11MAFLDArticle